Vulvar rhabdomyosarcoma
Rhabdomyosarcoma is a highly malignant tumor and the most common soft tissue sarcoma in children. 20% of them occur in the pelvis and reproductive tract. Foreign studies have found that rhabdomyosarcoma in the female reproductive tract accounts for about 3.5%. Among them, vulvar rhabdomyosarcoma (accounting for 13%). It is easy to occur around the labia majora, clitoris and urethra. The tumor grows fast and metastasizes early.
-
Site of disease:
vulva -
Infectious :
Not contagious -
Frequent population:
The most common soft tissue sarcoma in children -
Related symptoms:
Swelling of the vulva Vaginal bleeding Pubic area lump Ulcers with cauliflower-like appearance Loss of appetite -
Concurrent disease:
Related Drugs
Cisplatin for injection
Indication: It is a first-line drug for the treatment of various solid tumors. Combination with VP-16 (EP regimen) is a first-line regimen for the treatment of SCLC or NSCLC. Combination with MMC, IFO (IMP regimen), or NVB is a common regimen for the treatment of NSCLC. Combination chemotherapy based on DDP is also the main treatment for advanced ovarian cancer, osteosarcoma and neuroblastoma. Combination with ADM, CTX, etc. is effective for squamous cell carcinoma and transitional cell carcinoma in multiple sites, such as head and neck, cervix, esophagus and urinary system tumors. "PVB" (DDP, VLB, BLM) can treat most stage IV non-spermatogonia testicular cancers with a remission rate of 50% to 80%. In addition, this product is a radiotherapy sensitizer. It is currently widely used in foreign countries for local radiotherapy of stage IV inoperable NSCLC, which can improve efficacy and survival.
Manufacturer:
Jinzhou Jiutai Pharmaceutical Co., Ltd.
Related Ingredients